Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11F3N2O2 |
| Molecular Weight | 260.2124 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N1CC(C1)OC2=CC(=CC=C2)C(F)(F)F
InChI
InChIKey=LIAILJLSVRAGSM-UHFFFAOYSA-N
InChI=1S/C11H11F3N2O2/c12-11(13,14)7-2-1-3-8(4-7)18-9-5-16(6-9)10(15)17/h1-4,9H,5-6H2,(H2,15,17)
| Molecular Formula | C11H11F3N2O2 |
| Molecular Weight | 260.2124 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dezinamide is a potential antiepileptic drug that binds to the voltage-sensitive sodium channel. It is a metabolite of fluzinamide. It was active in preventing maximal seizures induced in mice or rats by electroshock and threshold seizures induced in mice by metrazol, bicuculline, and picrotoxin. It was predominantly active against tonic-clonic seizures. Adverse experiences included headache, ataxia, blurred vision, diplopia, dizziness, lightheadedness, and mild confusion. Dezinamide development was discontinued because of toxicity problems not observed with the metabolite.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1733743
Single 400 mg dose
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:27 GMT 2025
by
admin
on
Mon Mar 31 18:10:27 GMT 2025
|
| Record UNII |
C85G40F6YS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EE-12
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104646
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
146291
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
DTXSID40238406
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
SUB07058MIG
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
91077-32-6
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
100000082901
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
C85G40F6YS
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
C171702
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY | |||
|
6991
Created by
admin on Mon Mar 31 18:10:27 GMT 2025 , Edited by admin on Mon Mar 31 18:10:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|